Capsida Biotherapeutics to Present Broad Pipeline and Platform Advances at ASGCT 2025 Annual Meeting Capsida Biotherapeutics (“Capsida”), a biotechnology company focused on developing targeted gene therapies for serious neurological and systemic disorders, announced today that it will present significant new…
Strand Therapeutics Unveils Groundbreaking Preclinical Data for STX-003, a Programmable mRNA Therapy Targeting Solid Tumors Strand Therapeutics Inc., a biotechnology company pioneering programmable mRNA technology to develop curative therapies for cancer and other serious diseases, has announced the upcoming presentation…
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage biotechnology company committed to developing transformative genetic medicines for patients and families affected by rare neurological diseases, has announced its upcoming participation in the 28th Annual Meeting of the American Society for Gene and…
Personalis’ NeXT Personal® Demonstrates 100% Early Detection of Colorectal Cancer Relapses Ahead of Imaging in Interim VICTORI Study Results Presented at the 2025 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois, the findings show that…
Affinia Therapeutics to Present Breakthrough Data on AFTX-201, Novel BBB-Penetrant AAV Capsids, and Proprietary Manufacturing Advancements at ASGCT 2025 Affinia Therapeutics, a pioneering gene therapy company focused on developing potentially curative treatments for severe cardiovascular and neurological diseases, has announced…
Susan G. Komen® Applauds Bipartisan Reintroduction of the Access to Breast Cancer Diagnosis Act to Eliminate Financial Barriers to Life-Saving Imaging Susan G. Komen®, the world’s leading breast cancer organization, has praised a major bipartisan and bicameral effort in Congress…
Transverse Medical Inc. Successfully Completes Series B2 Financing Round to Advance Stroke Prevention Technology A pioneering early-stage medical device company specializing in Cerebral Embolic Protection (CEP) for stroke prevention during Transcatheter Aortic Valve Replacement (TAVR) procedures, today announced the successful…
Pfizer’s Sasanlimab Combination Significantly Extends Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer Patients Pfizer Inc. (NYSE: PFE) today announced encouraging results from the pivotal Phase 3 CREST trial, evaluating the efficacy and safety of sasanlimab, an investigational anti-PD-1…
UroGen Pharma Announces Promising Early Results from Phase 1 Study Evaluating UGN-301 for Non-Muscle Invasive Bladder Cancer UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company committed to developing and commercializing innovative therapies for urothelial and specialty cancers, today announced positive…
Merck KGaA, Darmstadt, Germany, to Acquire SpringWorks Therapeutics in Strategic Move to Accelerate Healthcare Growth Merck KGaA, Darmstadt, Germany (DAX: MRK), a global leader in science and technology, today announced that it has entered into a definitive agreement to acquire…